Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lead-in observational study before BAY2599023 gene therapy in severe hemophilia A
NL-OMON51102Phase 3Withdrawn
- Sponsor
- Bayer
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of peboctocogene camaparvovec and Factor VIII in hemophilia A, sponsored by Bayer. Primary endpoint: Annualized bleeding rate. Planned start Jul 2021; status: withdrawn.
02
Drugs
peboctocogene camaparvovecFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON51102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51102.